Other
Relapsing Polychondritis
10
Pipeline Programs↗
2
Active Trials↗
6
Companies Involved↗
Relapsing Polychondritis is an early-stage landscape with 10 programs across 6 companies. The most active players are Bristol-Myers Squibb, Iovance Biotherapeutics, Inc., Alnylam Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 29
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
10programs
Small molecule440%
Monoclonal antibody330%
Protein / enzyme330%
Modality classified for 100% of 10 pipeline programs.
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Recruiting2 · 33%
Withdrawn1 · 17%
Clinical Trials
Trial Activity
6 trials
Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Completed·—·N/A·NCT01041248·1 enrolled
Study on the Safety of Abatacept in Relapsing Polychondritis
Completed·—·Phase 1·NCT01272856·4 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)